Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT (2016 - 2025)

Adma Biologics (ADMA) has disclosed EBT for 13 consecutive years, with $61.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 77.44% year-over-year to $61.6 million, compared with a TTM value of $182.7 million through Dec 2025, up 45.29%, and an annual FY2025 reading of $182.7 million, up 45.29% over the prior year.
  • EBT was $61.6 million for Q4 2025 at Adma Biologics, up from $47.5 million in the prior quarter.
  • Across five years, EBT topped out at $61.6 million in Q4 2025 and bottomed at -$18.8 million in Q2 2021.
  • Average EBT over 5 years is $8.9 million, with a median of -$1.9 million recorded in 2023.
  • The sharpest move saw EBT decreased 4.98% in 2021, then skyrocketed 1332.71% in 2024.
  • Year by year, EBT stood at -$16.5 million in 2021, then rose by 28.55% to -$11.8 million in 2022, then skyrocketed by 189.84% to $10.6 million in 2023, then surged by 227.64% to $34.7 million in 2024, then soared by 77.44% to $61.6 million in 2025.
  • Business Quant data shows EBT for ADMA at $61.6 million in Q4 2025, $47.5 million in Q3 2025, and $40.1 million in Q2 2025.